Hengrui Looks Abroad For Strategic In-Licensing Deal
This article was originally published in PharmAsia News
Executive Summary
Jiangsu Hengrui has tested new waters to in-license its first drug candidate from overseas under an exclusive licensing agreement with Tesaro, marking its ambition to increase international collaborations under its development strategy for this year. Some analysts predict the deal may be just the start of a broader relationship.